# Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years

> **NCT02102698** · PHASE2 · COMPLETED · sponsor: **Emalex Biosciences Inc.** · enrollment: 40 (actual)

## Conditions studied

- Tourette's Syndrome

## Interventions

- **DRUG:** Ecopipam

## Key facts

- **NCT ID:** NCT02102698
- **Lead sponsor:** Emalex Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02102698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02102698, "Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02102698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*